Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-01-19

FDA Approved: KESIMPTA — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for Kesimpta (ofatumumab) submitted by Novartis Pharmaceuticals Corporation. This action updates the product's labeling/…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Kesimpta (ofatumumab)

Snippet

SUPPL AP for KESIMPTA (OFATUMUMAB)